
Doximity, Inc.

DOCS (Doximity, Inc.) trades at 6.1x EV/Revenue — reasonably priced for a physician network platform company with best-in-class gross margins (90%) and moderate growth (+13% YoY). The business is highly profitable at 42% EBIT margins. Forward PE of 16x.
80% of day traders lose money. The average holding period of a stock on the NYSE is now just 5.5 months — down from 8 years in 1960.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
Doximity operates the largest professional network for healthcare professionals in the US, connecting 85% of US physicians and two-thirds of nurse practitioners/PAs through its platform. The company monetizes this network by helping pharmaceutical companies reach and engage with healthcare providers through targeted digital marketing, telehealth solutions, and increasingly, AI-powered tools. Think "LinkedIn for doctors" with a business model focused on pharma advertising dollars.
Revenue growth has decelerated from double-digits to mid-single digits, with FY26 guidance calling for 13% growth to $643M after a strong Q3 beat. The company expects to return to double-digit growth by exiting 2026, driven by AI product commercialization and outpacing the ~5% healthcare digital marketing market growth. January 2026 bookings showed the highest growth rate since going public after pharma budget delays cleared.
Doximity maintains best-in-class profitability with 90%+ gross margins and 55-60% adjusted EBITDA margins, generating strong free cash flow ($58.5M in Q3 alone). Management has committed to maintaining 50%+ EBITDA margins as a "floor" even while investing heavily in AI infrastructure and development, demonstrating the underlying strength of their high-margin advertising model.
Doximity has built an almost insurmountable network effect moat with 85% physician penetration in the US, making it indispensable for pharma companies' digital marketing strategies. While facing competition from emerging AI healthcare platforms, the company's physician-first approach and peer validation system for AI answers differentiates it from pure-play AI competitors who lack established physician relationships and trust.
Q3 delivered strong execution with 10% revenue growth, 28% revenue beat, and 60% EBITDA margins exceeding guidance by 700 basis points. However, pharma budget delays due to MFN policy uncertainty pushed typical Q4 bookings into Q1 2026, creating near-term growth lumpiness despite underlying business strength. The delayed bookings materialized in January with record growth rates.
Analysts remain cautiously optimistic about the long-term AI opportunity while concerned about near-term pharma budget headwinds and policy uncertainty. There's strong interest in the AI monetization timeline and competitive positioning, with consensus expecting steady but unspectacular growth until AI products fully launch. The consistent earnings beats and margin expansion have maintained analyst confidence in execution.
Doximity is a profitable, cash-generating monopoly on US physician networks that's successfully navigating the transition from a pure advertising platform to an AI-powered healthcare infrastructure company, though investors must weather pharma budget volatility in the near term.
| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | $570M | $643M | $701M | $768M |
| Growth | — | +13% | +9% | +10% |
| EBITDA | — | $328M | $354M | $396M |
| Growth | — | +8% | +12% | |
| FCF | $267M | $316M | $342M | $385M |
| Margin | 47% | 49% |
Doximity Study Finds Physicians Rapidly Adopting AI, But Accuracy Concerns Persist
Baron Health Care Fund Q4 2025 Contributors And Detractors
Halper Sadeh LLC Encourages Doximity Inc. Shareholders to Contact the Firm to Discuss Their Rights
Doximity: Growth Outlook Is Murky
Stock Market Today: Futures Point Higher After Indexes Dive; Nasdaq, S&P 500 Poised for Weekly Losses; Bitcoin Sinks Near $60,000 Before Rebounding
| 49% |
| 50% |
| EPS (PF) | $1.11 | $1.55 | $1.62 | $1.80 |
| Growth | — | +39% | +5% | +11% |
| PF Op Inc | — | $396M | $430M | $481M |